

DHRS2 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP5339b**Specification**

DHRS2 Antibody (C-term) Blocking peptide - Product Information

Primary Accession [O13268](#)
Other Accession [NP_878912.1](#)

DHRS2 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 10202

Other Names

Dehydrogenase/reductase SDR family member 2, mitochondrial, 111-, Dicarboxyl reductase
HEP27, Protein D, DHRS2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

DHRS2 Antibody (C-term) Blocking peptide - Protein Information

Name DHRS2 ([HGNC:18349](#))

Synonyms SDR25C1

Function

NADPH-dependent oxidoreductase which catalyzes the reduction of dicarbonyl compounds. Displays reductase activity in vitro with 3,4- hexanedione, 2,3-heptanedione and 1-phenyl-1,2-propanedione as substrates (PubMed:16685466). May function as a dicarbonyl reductase in the enzymatic inactivation of reactive carbonyls involved in covalent modification of cellular components (PubMed:16685466). Also displays a minor hydroxysteroid dehydrogenase activity toward bile acids such as ursodeoxycholic acid (UDCA) and isoursodeoxycholic acid (isoUDCA), which makes it unlikely to control hormone levels (PubMed:16685466). Doesn't show any activity in vitro with retinoids and sugars as substrates (PubMed:16685466). Attenuates MDM2-mediated p53/TP53 degradation, leading to p53/TP53 stabilization and increased transcription activity, resulting in the accumulation of MDM2 and CDKN1A/p21 (PubMed:20547751). Reduces proliferation, migration and invasion of cancer cells and well as the production of ROS in cancer (PubMed:29106393).

Cellular Location

Mitochondrion matrix. Nucleus. Note=A minor fraction of the protein is translocated from the mitochondria to the nucleus, after cleavage of the targeting signal

Tissue Location

Widely expressed, with highest levels in liver and kidney, followed by heart, spleen, skeletal muscle and placenta. In hemopoietic cells, expressed in dendritic cells, but not in monocytes, macrophages, granulocytes, nor in B and T lymphocytes

DHRS2 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

DHRS2 Antibody (C-term) Blocking peptide - Images**DHRS2 Antibody (C-term) Blocking peptide - Background**

DHRS2 displays NADPH-dependent dicarbonyl reductase activity in vitro with 3,4-Hexanedione, 2,3-Heptanedione and 1-Phenyl-1,2-propanedione as substrates. DHRS2 do not reductase activity is displayed in vitro with steroids, retinoids and sugars as substrates. This protein may inhibit cell replication.

DHRS2 Antibody (C-term) Blocking peptide - References

Monge, M., et al. Carcinogenesis 30(8):1288-1297(2009)Persson, B., et al. Chem. Biol. Interact. 178 (1-3), 94-98 (2009) Shafqat, N., et al. Cell. Mol. Life Sci. 63(10):1205-1213(2006)